MoneyWorks4Me

Gland Pharma gets EIR from USFDA for Hyderabad facility

16 Jan 2025 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Dundigal facility at Hyderabad. 

USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 22, 2024 and July 25, 2024.  The inspection was concluded with two 483 Observations.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Peers
Company Name CMP
Sun Pharma. Inds. 1868.00
Dr. Reddys Labs. 1202.00
Cipla 1385.00
Lupin 2120.00
Zydus Lifesciences 1161.50
View more..